Floyd K, Glaziou P, Zumla A, Raviglione M , 2018. The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the end TB era. Lancet Respir Med 6: 299–314.
Churchyard G, Kim P, Shah NS, Rustomjee R, Gandhi N, Mathema B, Dowdy D, Kasmar A, Cardenas V , 2017. What we know about tuberculosis transmission: an overview. J Infect Dis 216 (Suppl 6):S629–S635.
WHO , 2020. Global Tuberculosis Report. Available at: https://www.who.int/teams/global-tuberculosis-programme/data.
Gygli SM, Borrell S, Trauner A, Gagneux S , 2017. Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. FEMS Microbiol Rev 41: 354–373.
Suárez I, Fünger SM, Rademacher J, Fätkenheuer G, Kröger S, Rybniker J , 2019. The diagnosis and treatment of tuberculosis. Dtsch Arztebl Int 116: 729–735.
Cohen KA, Bishai WR, Pym AS , 2014. Molecular basis of drug resistance in Mycobacterium tuberculosis. Microbiol Spectr 2: 1–16.
McBryde ES, Meehan MT, Doan TN, Ragonnet R, Marais BJ, Guernier V, Trauer JM , 2017. The risk of global epidemic replacement with drug-resistant Mycobacterium tuberculosis strains. Int J Infect Dis 56: 14–20.
Onyedum CC, Alobu I, Ukwaja KN , 2017. Prevalence of drug-resistant tuberculosis in Nigeria: a systematic review and metaanalysis. PLoS One 12.
Brady P, Vita D , 2018. Challenges to tuberculosis control in Angola: the narrative of medical professionals. J Public Heal (United Kingdom) 40: 820–826.
Aznar ML et al.2019. Prevalence and risk factors of multidrug-resistant tuberculosis in Cubal, Angola: a prospective cohort study. Int J Tuberc Lung Dis 23: 67–72.
Lienhardt C, Glaziou P, Uplekar M, Lönnroth K, Getahun H, Raviglione M , 2012. Global tuberculosis control: lessons learnt and future prospects. Nat Rev Microbiol 10: 407–416.
MacGregor-Fairlie M, Wilkinson S, Besra GS, Oppenheimer PG , 2020. Tuberculosis diagnostics: overcoming ancient challenges with modern solutions. Emerg Top Life Sci 4: 435–448.
National Institute of Statistics , 2016. Resultados Definitivos Do Recenseamento Geral Da População e Da Habitação de Angola—2014. Available at: http://www.effaangola.org/AngolaCensus2014_ResultadosDefinitivos_Mar2016.pdf.
Kehinde AO, Obaseki FA, Ishola OC, Ibrahim KD , 2007. Multidrug resistance to Mycobacterium tuberculosis in a tertiary hospital. J Natl Med Assoc 99: 1185–1189.
World Health Organization , 2020. Tuberculosis Surveillance and Monitoring in Europe. Geneva, Switzerland: WHO.
Moreira A da SR, Kritski AL, Carvalho ACC , 2020. Social determinants of health and catastrophic costs associated with the diagnosis and treatment of tuberculosis. J Bras Pneumol 46: 1–5.
Siroka A, Lönnroth K, Ponce N , 2016. The impact of social protection on tuberculosis rates: a global analysis. Lancet Infect Dis 16: 473–479.
Abanda NN, Djieugoué JY, Lim E, Pefura-Yone EW, Mbacham WF, Vernet G, Penlap VM, Eyangoh SI, Taylor DW, Leke RGF , 2017. Diagnostic accuracy and usefulness of the Genotype MTBDRplus assay in diagnosing multidrug-resistant tuberculosis in Cameroon? A cross-sectional study. BMC Infect Dis 17: 1–10.
Valencia S et al.2017. Tuberculosis drug resistance in southern Mozambique: results of a population-level survey in the district of Manhiça. Int J Tuberc Lung Dis 21: 446–451.
Affolabi D, Sanoussi N, Codo S, Sogbo F, Wachinou P, Massou F, Kehinde A, Anagonou S , 2017. First insight into a nationwide genotypic diversity of Mycobacterium tuberculosis among previously treated pulmonary tuberculosis cases in Benin, West Africa. Can J Infect Dis Med Microbiol 2017: 6–11.
Adane K, Ameni G, Bekele S, Abebe M, Aseffa A , 2015. Prevalence and drug resistance profile of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients attending two public hospitals in East Gojjam zone, northwest Ethiopia infectious disease epidemiology. BMC Public Health 15: 1–8.
Thapa G, Pant ND, Khatiwada S, Iekhak B, Shrestha B , 2016. Drug susceptibility patterns of the Mycobacterium tuberculosis isolated from previously treated and new cases of pulmonary tuberculosis at German–Nepal tuberculosis project laboratory, Kathmandu, Nepal. Antimicrob Resist Infect Control 5: 1–7.
Stosic M, Vukovic D, Babic D, Antonijevic G, Foley KL, Vujcic I, Grujicic SS , 2018. Risk factors for multidrug-resistant tuberculosis among tuberculosis patients in Serbia: a case-control study. BMC Public Health 18: 91–96.
Lomtadze N, Aspindzelashvili R, Janjgava M, Mirtskhulava V, Wright A, Blumberg HM, Salakaia A , 2009. Prevalence and risk factors for multidrug-resistant tuberculosis in the Republic of Georgia: a population-based study. Int J Tuberc Lung Dis 13: 68–73.
Fregona G, Cosme LB, Moreira CMM, Bussular JL, do Valle Dettoni V, Dalcolmo MP, Zandonade E, Maciel ELN , 2017. Risk factors associated with multidrug-resistant tuberculosis in Espírito Santo, Brazil. Rev Saude Publica 51: 41.
Otokunefor K, Otokunefor TV, Omakwele G , 2018. Multi-drug resistant Mycobacterium tuberculosis in Port Harcourt, Nigeria. Afr J Lab Med 7: 1–4.
Ba Diallo A et al.2017. Emergence and clonal transmission of multi-drug-resistant tuberculosis among patients in Chad. BMC Infect Dis 17: 1–7.
Coelho AGV, Zamarioli LA, Telles MA, Ferrazoli L, Waldman EA , 2012. A study of multidrug-resistant tuberculosis in risk groups in the city of Santos, São Paulo, Brazil. Mem Int Oswaldo Cruz 107: 760–766.
Musa BM, Adamu AL, Galadanci NA, Zubayr B, Odoh CN, Aliyu MH , 2017. Trends in prevalence of multi drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis. PLoS One 12: 1–15.
Hattori T, Kobayashi N, Nagai H, Chagan-Yasutan H, Telan E, Solante MB , 2016. Nationwide HIV-, MDR-TB survey in Japan and collaborative study in the Philippines. Int J Mycobacteriol 5: S18–S19.
Akhtar AM, Arif MA, Kanwal S, Majeed S , 2016. Prevalence and drug resistance pattern of MDR TB in retreatment cases of Punjab, Pakistan. J Pak Med Assoc 66: 989–993.
National Institute of Statistics , 2016. Inquérito de Indicadores Múltiplos e de Saúde (IIMS) Em Angola. Available at: https://dhsprogram.com/pubs/pdf/FR327/FR327.pdf.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||95||73||5|
Tuberculosis (TB) is a major cause of illness and public health concern, especially in resource-limited countries. This study analyzed the characteristics related to anti-TB drug resistance. Moreover, we examined the evidence-based indications for the treatment of active TB in Angola. This study evaluated the medical records of 176 patients screened for TB from January to September 2016 in Luanda, the capital city of Angola. Approximately 66.5% of the patients were newly diagnosed with active TB. The residence area showed a significant relationship with TB (P = 0.025), whereas age group (P = 0.272), gender (P = 0.853), and HIV status (P = 0.284) did not showed any relationship with TB. Overall, 72.4% of TB patients had resistance to at least one of the anti-TB drugs. The risk of anti-TB drug resistance was higher in males (odds ratio [OR]: 1.22; 95% confidence interval [CI]: 0.42–3.58, P = 0.685] and in TB-HIV coinfected patients [OR: 1.39; (95% CI: 0.26–7.28), P = 0.700], whereas it was lower in patients aged 30 years or older (OR: 0.56; 95% CI: 0.18–1.69) P = 0.303) and in patients living in urbanized areas (OR: 0.74; 95% CI: 0.17–3.25; P = 0.685). Our findings showed that drug-resistant TB is emerging in Angola. Further studies on factors related to anti-TB drug resistance are urgently needed to ascertain the magnitude of the problem and to proffer strategies toward TB control in Angola.
Financial support: This research did not receive any specific grant from agencies in the public, commercial, or not-for-profit sectors.
Authors’ addresses: Cruz S. Sebastião, Instituto Nacional de Investigação em Saúde (INIS), Luanda, Angola, Centro de Investigação em Saúde de Angola (CISA), Angola, and Instituto Superior de Ciências da Saúde, Universidade Agostinho Neto, Luanda, Angola, E-mail: email@example.com. João Samulengo, Euclides Sacomboio, Ngiambudulu M. Francisco, Carlos Teixeira, Samuel António, Zoraima Neto, Joana Paixão, António Mateus, Zinga David, and Joana Morais, Instituto Nacional de Investigação em Saúde (INIS), Luanda, Angola, E-mails: firstname.lastname@example.org, email@example.com, firstname.lastname@example.org, email@example.com, firstname.lastname@example.org, email@example.com, firstname.lastname@example.org, email@example.com, firstname.lastname@example.org, and email@example.com. Mizele Kinanga, Instituto Superior de Educação Física e Desporto, Luanda, Angola, E-mail: firstname.lastname@example.org. Joana Morais, Faculdade de Medicina, Universidade Agostinho Neto, Luanda, Angola, E-mail: email@example.com. Jocelyne Neto de Vasconcelos, Instituto Nacional de Investigação em Saúde (INIS), Luanda, Angola, and Centro de Investigação em Saúde de Angola (CISA), Angola, E-mail: firstname.lastname@example.org.